The H6PD Knockout MCF-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal cell population derived from the MCF-7 human breast adenocarcinoma line, featuring targeted disruption of the H6PD gene. This knockout model eliminates functional hexose-6-phosphate dehydrogenase (H6PD) expression, enabling rigorous investigation of its role in glucocorticoid metabolism and NADPH-dependent processes within a defined cellular context. As a polyclonal population, it reflects the heterogeneous editing outcomes typical of CRISPR/Cas9-mediated gene disruption, providing a robust loss-of-function system without requiring clonal isolation. The product is designed for researchers studying the intersection of redox biology and steroid hormone signaling, particularly in luminal A breast cancer models.
The MCF-7 host cell line is a well-characterized epithelial model of estrogen receptor-positive (ER+) breast adenocarcinoma, originally derived from a pleural effusion. These cells retain luminal A subtype features, including ER and progesterone receptor expression, and are widely employed to investigate hormone-responsive pathways. MCF-7 cells exhibit functional glucocorticoid receptor signaling, making them suitable for examining cortisone-to-cortisol conversion and its downstream effects on proliferation, apoptosis, and gene expression. The adherent, epithelial morphology supports reproducible culture conditions for assays monitoring metabolic and transcriptional changes.
H6PD encodes an endoplasmic reticulum (ER) luminal enzyme that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone, simultaneously reducing NADP+ to NADPH. This NADPH pool serves as an essential cofactor for 11??-hydroxysteroid dehydrogenase type 1 (11??-HSD1), which converts inactive cortisone to active cortisol. Cortisol subsequently binds the glucocorticoid receptor, promoting its nuclear translocation and transcriptional regulation of target genes such as FKBP5, GILZ, and SGK1. H6PD expression is transcriptionally regulated by PPAR?? and sterol regulatory element-binding proteins (SREBPs), linking metabolic signals to glucocorticoid activation. The enzyme interacts functionally with the hexose-6-phosphate transporter for substrate import and forms a coupled redox system with 11??-HSD1, establishing an ER-localized axis that controls local glucocorticoid availability independently of systemic cortisol levels.
In the MCF-7 breast cancer background, H6PD knockout disrupts the NADPH supply required for 11??-HSD1 activity, impairing intracellular cortisol regeneration and attenuating glucocorticoid receptor signaling. This perturbation alters the expression of glucocorticoid-responsive genes involved in cell survival, metabolism, and differentiation, offering a platform to dissect the role of local glucocorticoid action in ER+ breast cancer pathophysiology. Since elevated cortisol levels have been implicated in promoting mammary tumor cell proliferation and metabolic reprogramming, the model enables studies on how H6PD-driven NADPH production influences cancer cell phenotypes under varying redox conditions. The polyclonal nature of the knockout population further permits examination of bulk cellular responses without clonal bias.
Researchers can employ the H6PD Knockout MCF-7 Polyclonal Cells in diverse experimental settings. Western blotting and RT-qPCR confirm H6PD deletion and assess 11??-HSD1 or downstream target expression, while ELISA or LC-MS quantifies cortisol/cortisone ratios. NADP/NADPH ratio assays probe redox state changes, and glucocorticoid response element (GRE) reporter assays measure receptor activity. Functional studies include MTS/MTT proliferation assays and apoptosis detection. This model supports investigations into glucocorticoid sensitivity, metabolic syndrome-related pathways, and the interplay between NADPH homeostasis and oncogenic signaling in breast cancer. For additional technical details, please contact Ascent Research.
